Murelli M, Lignière G C
Minerva Med. 1984 May 7;75(19):1141-5.
The efficacy of proglumetacin , a new non-steroidal antiinflammatory drug, was assessed in 32 patients with rheumatoid arthritis. During treatment with 400-650 mg daily of proglumetacin over a period of 7-14 days, morning stiffness and side-effects were checked weekly or in severely ill patients daily. All patients but one completed the period of treatment. In spite of the short period of observation, a significant improvement was seen in the majority of cases (55%), while in 39% proglumetacin was not more effective than treatments before the admission to the study. In the group of patients treated for 14 days, morning stiffness parameters showed a significant improvement after 7 days and at the end of the period of study. Overall , only 3 patients referred side-effects: 1 case of transient headache and 2 cases of severe gastric pain. In our preliminary study, proglumetacin results to be effective as an antiinflammatory drug also in severe rheumatoid arthritis and safe for its low incidence of side-effects.
对32例类风湿性关节炎患者评估了一种新型非甾体抗炎药丙谷美辛的疗效。在为期7至14天的治疗期间，患者每日服用400 - 650毫克丙谷美辛，每周检查晨僵情况及副作用，病情严重的患者则每日检查。除1例患者外，所有患者均完成了治疗期。尽管观察期较短，但大多数病例（55%）有显著改善，而39%的患者中丙谷美辛并不比入组研究前的治疗更有效。在接受14天治疗的患者组中，晨僵参数在7天时及研究期末均有显著改善。总体而言，只有3例患者出现副作用：1例短暂性头痛和2例严重胃痛。在我们的初步研究中，丙谷美辛作为一种抗炎药，对重度类风湿性关节炎也有效，且副作用发生率低，较为安全。
